Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis	Arterial Occlusive Diseases, Disease Attributes, Infarction, Intracranial Atherosclerosis, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, arteriosclerosis disorder, atherosclerosis, brain disorder, brain infarction, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebral infarction, cerebrovascular disorder, intracranial arterial disease, intracranial arteriosclerosis, ischemic disease, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder	Not yet recruiting	Phase 3	2025-07-28		NCT06447701

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Central People's Hospital of Zhanjiang	7
Eighth Affiliated Hospital, Sun Yat-sen University	20
Guangdong Provincial People's Hospital	164
Guangzhou First People's Hospital	32
Peking University Shenzhen Hospital	48
Shantou Central Hospital	13
Shenzhen Second People's Hospital	31
Zhujiang Hospital	82

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.